Affiliations

  • PMID: 18830927

Review

Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes

Simon A Hinke. Curr Opin Mol Ther. 2008 Oct.

Abstract

Diamyd Medical AB is developing Diamyd (GAD-65), an alum formulation of a full-length recombinant human glutamic acid decarboxylase 65 for subcutaneous injection, for the potential prevention and treatment of type 1 diabetes (T1DM) or latent autoimmune diabetes (LADA) in adults. Phase II clinical trials indicated that Diamyd was safe and well tolerated in patients with T1DM or LADA. Diamyd is currently in phase II/III and III clinical trials for T1DM.

Similar articles

Cited by 5 articles

Publication types

MeSH terms

Substances

Reach out

Find us at the office

Ortlip- Vogeli street no. 79, 95103 Basseterre, Saint Kitts and Nevis

Give us a ring

Catharine Epson
+17 650 778 112
Mon - Fri, 11:00-22:00

Contact us